US Bancorp DE Has $152,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

US Bancorp DE cut its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 16.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,560 shares of the company’s stock after selling 2,472 shares during the quarter. US Bancorp DE’s holdings in Elanco Animal Health were worth $152,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. QRG Capital Management Inc. acquired a new position in Elanco Animal Health during the 4th quarter worth approximately $264,000. Proficio Capital Partners LLC acquired a new position in Elanco Animal Health during the 4th quarter worth approximately $405,000. Kovack Advisors Inc. acquired a new position in Elanco Animal Health during the 4th quarter worth approximately $170,000. Illinois Municipal Retirement Fund increased its position in Elanco Animal Health by 38.0% during the 4th quarter. Illinois Municipal Retirement Fund now owns 376,262 shares of the company’s stock worth $4,557,000 after purchasing an additional 103,692 shares in the last quarter. Finally, Skylands Capital LLC increased its position in Elanco Animal Health by 36.2% during the 4th quarter. Skylands Capital LLC now owns 504,500 shares of the company’s stock worth $6,109,000 after purchasing an additional 134,150 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 1.5 %

ELAN opened at $10.47 on Friday. Elanco Animal Health Incorporated has a twelve month low of $10.03 and a twelve month high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The company has a fifty day moving average of $11.46 and a 200-day moving average of $12.75. The stock has a market cap of $5.18 billion, a PE ratio of 26.16, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company earned $0.08 earnings per share. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on ELAN. Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Leerink Partners started coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target for the company. Piper Sandler decreased their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, UBS Group decreased their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average price target of $15.17.

Insiders Place Their Bets

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares of the company’s stock, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.57% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.